Ask about TB-500
Get a grounded answer across clinical evidence, community patterns, and risks.
TB-500
Also known as: Thymosin Beta-4 fragment
Synthetic peptide fragment
Mechanism of Action
May promote cell migration, tissue repair, and reduce inflammation. Research is primarily preclinical.
65% of 142 individuals in this dataset used TB-500 alongside BPC-157, making it one of the most frequently co-used healing peptides in observational data. TB-500 is a synthetic fragment of Thymosin Beta-4 associated with cell migration, tissue repair, and inflammation reduction in primarily preclinical research. It is not FDA-approved for human use and remains classified as a research compound.
Reported Outcomes
Clinical grade reflects published research; Community grade reflects user reports (n=1,216).
Improvements in skin quality, firmness, and appearance
Joint pain relief and mobility improvements
Accelerated recovery from injuries and surgery
Promotes recovery in models of nerve injury, traumatic brain injury, and lung fibrosis. Administration has been shown to improve sensorimotor function, promote axon regeneration, and alleviate organ damage.
Effects on sleep quality
Reduction in inflammation and swelling
Multiple studies consistently demonstrate potent anti-inflammatory effects in the eye, liver, and lung. The peptide reduces pro-inflammatory cytokines, downregulates NF-κB signaling, and decreases neutrophil and macrophage infiltration in injury models.
Wound healing and scar improvement
Accelerates healing in corneal and tympanic membrane models by promoting epithelial migration and barrier integrity. It acts synergistically with antibiotics to improve outcomes in bacterial keratitis.
Tendon and ligament repair and health
In vitro studies utilizing electrospun scaffolds loaded with Thymosin Beta-4 indicate it may promote migration, proliferation, and tenogenic differentiation of mesenchymal stem cells.
Changes in energy and fatigue levels
Anti-aging and regenerative effects
Effects on mood and cognitive function
In a rat model of traumatic brain injury, the peptide fragment AcSDKP improved spatial learning and sensorimotor functional recovery.
Muscle recovery and repair from exercise or injury
Gut lining repair and digestive health
Effects on hair growth and quality
Who Discusses TB-500
From community reports with demographic data.
Gender
n=85
Age Distribution (limited data)
n=37
Side Effects
Limited dataBased on 14 user reports (n=14). Frequency indicates how often each was mentioned.
Uncommon (1-5%)
Risks & Warnings
Important safety considerations based on clinical data and community reports.
Psychiatric Effects
Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.
Injection Pain/Stinging
Users report less sting with more dilution and slower injection; light massage can help.
Injection Site Reactions
Local reactions are common and usually mild. Rotate injection sites.
Dosing
Standard Protocol
- Starting Dose
- 2-2.5mg twice weekly (loading), then weekly
- Titration
- No established protocol
- Half-life
- Unknown in humans
- Administration
- Subcutaneous or intramuscular injection
Community Dosing Patterns
Based on 110 mentions
Community-reported patterns, not medical advice.
Pricing
Research-grade reference pricing for 10mg vial. Prices vary by vendor and quantity. Research chemicals require self-mixing and lack medical oversight. Shipping is not included.
We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.
US Research Grade
Single small vial from US domestic vendors
US Research (Bulk)
Per-dose equivalent when buying larger US vials
China Research
Per-vial when buying 10-pack from Chinese vendors
Research
Key Studies
J Public Health Res (2024)
Molecules (2023)
Front Zool (2023)
Cells (2023)
Int Immunopharmacol (2023)
Commonly Stacked With
From community members' documented stacks involving TB-500.
Switching Patterns
Based on 79 discussions about switching to or from TB-500.
→ Switching FROM
Users who switched to TB-500
← Switching TO
Users who switched from TB-500